RAIN - Rain Therapeutics to Present at Upcoming Virtual Investor Conferences
B. Riley Securities virtual presentation scheduled for January 27 th at 3:30 pm ET
Guggenheim Oncology virtual fireside chat scheduled for February 10 th at 4:00 pm ET
NEWARK, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview at the B. Riley Securities Oncology Investor Conference on Thursday, January 27 th at 3:30 pm ET, and Rain will be highlighted in a virtual fireside chat at the Guggenheim Oncology Conference with research analyst Michael Schmidt on Thursday, February 10 th at 4:00 pm ET. The fireside chat will feature an interactive discussion with Rain’s co-founder, chairman and CEO, Avanish Vellanki.
Additional details can be found below:
Conference: B. Riley Securities Oncology Investor Conference
Date and Time: Thursday, January 27 th , 2022 at 3:30-4:00 pm ET.
Registration: Webcast link here .
Conference: Guggenheim Oncology Conference
Date and Time: Thursday, February 10 th , 2022 at 4:00-4:25 pm ET.
Registration: Webcast link here .
Replays of the corporate overview presentation and fireside chat will be available by visiting the " Events " section of the Rain website after the conclusion of the events and will be archived on the Rain website for 30 days.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com